Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 92 Lung Neoplasms 32 NSCLC 7 Brain Neoplasms 7 Meningeal Carcinomatosis 4 Neoplasm Metastasis 3 Carcinoma, Squamous Cell 2 Bronchial Neoplasms 2 Adenocarcinoma of Lung 2 Small Cell Lung Carcinoma 1 Sexual Dysfunction, Physiological 1 Resectable Non-small Cell Lung Cancer 1 Rare Tumour 1 Prostatic Neoplasms 1 Progression Free Survival 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Non-small Cell Carcinoma 1 Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1 Non-Small Cell Lung Cancer With EGFR T790M Mutation 1 Non-Small Cell Lung Cancer With EGFR Mutation 1 Non Small Cell Lung Cancer Metastatic 1 Neurocognitive 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Lung Cancer Metastatic 1 Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) 1 Glioblastoma 1 Eunuchism 1 Erectile Dysfunction 1

Interventions

Pemetrexed 2 rofecoxib 1 pembrolizumab 1 paclitaxel poliglumex 1 osimertinib 1 aumolertinib 1 atezolizumab 1 anlotinib 1 Radiosurgery 1 RO5126766 1 Nivolumab 1 Gemcitabine 1 Drug Therapy 1 Cisplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Non-small Cell Lung Cancer × osimertinib × Clear all

NCT05489731 2023-06-15

VIC-1911

Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.

Phase 1 Unknown

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡